

# For the Health

## **Advancing Embryo Selection: Combined DNA and RNA Analysis in PGT**


**Dr. Taoli Ding**  
**April 9, 2025**

# of Billions

# | Disclosure

- Dr. Taoli Ding
- Full-time employee, R&D project manager of Yikon Genomics

# Thirty years development of PGT-A




Niederberger C, Pellicer A, Cohen J, et al. Forty years of IVF. Fertil Steril. 2018;110(2):185-324.e5.

Takeuchi K. Pre-implantation genetic testing: Past, present, future. Reprod Med Biol. 2020;20(1):27-40.

# | Current challenges faced by PGT-A





Hernández-Vargas P, et al. Identifying biomarkers for predicting successful embryo implantation: applying single to multi-OMICS to improve reproductive outcomes. Hum Reprod Update. 2020;26(2):264-301.



OPEN

## Human blastocysts of normal and abnormal karyotypes display distinct transcriptome profiles


Frederick Licciardi<sup>1</sup>, Tenzin Lhakhang<sup>2</sup>, Yael G. Kramer<sup>3</sup>, Yutong Zhang<sup>4</sup>, Adriana Heguy<sup>4,5,6</sup> & Aristotelis Tsirigos<sup>2,5,6</sup>

Received: 16 March 2018

Accepted: 26 September 2018

Published online: 08 October 2018

Embryos with abnormalities of trisomies and monosomies display special characteristics of transcriptome profiles compared with normal embryos.



# A proof-of-concept study for multi-omics PGT






Human Reproduction, 2024, 00(0), 1–12

<https://doi.org/10.1093/humrep/deae237>

Original Article


## Reproductive genetics

## Multi-omics PGT: re-evaluation of euploid blastocysts for implantation potential based on RNA sequencing

Jiamin Jin<sup>1,2,†</sup>, Jieliang Ma<sup>3,4,†</sup>, Xiufen Wang<sup>1,2</sup>, Fang Hong<sup>1,2</sup>, YinLi Zhang <sup>1,2</sup>, Feng Zhou<sup>1,2</sup>, Cheng Wan<sup>3,4</sup>, Yangyun Zou<sup>3,4</sup>, Ji Yang<sup>3,4</sup>, Sijia Lu <sup>3,4,\*</sup>, and Xiaomei Tong <sup>1,2,\*</sup>



# Study design






# Results 1- Summary of PGT-A results


- CNVs were successfully detected in **99.8% (411/412)** of cases. Of the 412 blastocysts, **60.4% (249/412)** tested as **euploid embryos**.
- In the transferrable subgroup, the rates of euploidy, aneuploidy, and mosaicism among embryos were 68.4% (249/364), 16.5% (60/364), and 14.8% (54/364), respectively.
- Among the 96 aneuploidies (23.3% overall), the rates of whole chromosomal, segmental, and whole and segmental aneuploidies were 53.13%, 33.33%, and 13.54%, respectively.
- Furthermore, chromosomes 16, 21, and 22 were the top three whole chromosome aneuploidies.

Characteristic		P-value
No. of patients	102	
Oocyte retrieval cycles	111	
Maternal age (years)	33 (30, 36)	
Maternal BMI (kg/m <sup>2</sup> )	20.90 (19.30, 23.10)	
Basal FSH (mIU/ml)	7.10 (5.90, 8.35)	
Basal LH (mIU/ml)	3.99 (3.17, 5.30)	
Basal E2 (pg/ml)	27.40 (20.95, 34.70)	
AMH (ng/ml)	3.35 (2.07, 4.55)	
No. oocytes	11 (6, 17)	
No. MII oocytes	10 (5, 14)	
No. 2PN zygotes	7 (4, 10)	
Biopsied blastocysts per cycle	3 (2, 5)	
High-quality rate of Day 5 blastocysts (%)	57.7% (146/253)	0.020
High-quality rate of Day 6 blastocysts (%)	46.6% (88/189)	
Embryos for PGT	412	
Success rate of PGT (%)	99.8% (411/412)	





## Results 2- RNA-seq characteristics for aneuploidy

- The second fraction of each biopsy lysate was reverse-transcribed to cDNA, and the library was constructed. 10 M reads were obtained for each RNA library, in which the average exonic rate was 26.4%.
- We demonstrate a pronounced gene dosage effect, where genes tend to be under-expressed with the lost chromosomes in the case of monosomy, whereas in trisomy, genes in the extra chromosome show overexpression.
- CNVs inferred based on the fragments per kilobase million (FPKM) also showed the enriched gain (red region) or loss (blue region) panels in chromosomes 16, 21, and 22, which coincided with the CNVs of the PGT results.
- DEGs between aneuploidy and euploidy (chr 16) are essential for viability and fundamental for early embryonic development.



# Results 3- Transcriptome characteristics of blastocysts

- When comparing D5 euploid blastocysts with D6 euploid blastocysts, 163 over-regulated and 24 under-regulated genes were detected.
- Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway and gene ontology (GO) analyses demonstrated that DEGs were mainly associated with the carboxylic acid transport, cell differentiation involved in embryonic placenta development, inflammatory mediator regulation of TRP channels, **PPAR signaling pathway (FABP3, PLIN5, EHHADH, and PPARG)**, and **Notch signaling pathway (HEY2, DLL4, and TLE6)**, of which the latter two pathways are associated with **trophoblast differentiation** and **placental formation**.



## Significant DEGs in the KEGG pathway


FABP3, PLIN5, EHHADH, PPARG

HEY2, DLL4, TLE6

# Results 4- Dialog between blastocysts and endometrium

- The protein-protein interaction network (PPIN) showed 185 nodes, 327 edges connecting 187 D5/D6 DEGs, and 199 critical genes for the receptive endometrium.
- Three clusters were involved in the implantation process.
- All three clusters implied that the **embryo was further differentiated for post-implantation development**, as **the endometrium was also undergoing epithelial cell differentiation to facilitate adhesion for the blastocysts**.

● DEGs between D5/D6 embryos  
▲ Critical genes for endometrial receptivity



Blastocyst cell fate commitment and endoderm formation


Amino acid transmembrane transport and vascular transport between the endometrium and blastocyst

Endometrial preparation




# Results 5- Ranking model for embryo implantation


- 83 transferred embryos were left for the construction of an optimal predictive model based on the transcriptome changes associated with clinical pregnancy outcomes.
- Of all the 83 embryos, 59 embryos were randomly assigned to the training set and the remaining 24 embryos formed the test set for machine learning.
- There were **280 DEGs** identified between the successful clinical pregnancy group and failed clinical pregnancy groups.



**280 DEGs** identified from 34 successful clinical pregnancy embryos and 25 failed embryos



Predictive model test with three different machine learning models (24 samples)




A retrospective analysis of all 83 euploidy blastocysts


RF = random forest    VM = support vector machine    LDA = linear discriminant analysis

## Results 5- Ranking model for embryo implantation

- Based on the probability (prob) of the RF prediction, 83 euploid blastocysts were divided into three groups: good (prob  $\geq 0.6$ ), moderate ( $0.5 \leq \text{prob} < 0.6$ ), and poor (prob  $< 0.5$ ).
- The implantation rate was significantly higher in the good group than in the moderate group (88.6% vs 50.0%,  $P = 0.001$ ). In addition, the implantation rate was higher in the moderate group than in the poor group (50.0% vs 20.8%,  $P = 0.035$ ). Moreover, the implantation rate in the good group was significantly higher than the original implantation rate (88.6% vs 57.8%,  $P = 0.001$ ).
- Among all of the 213 euploid blastocysts with RNA-seq results, 36.6%, 36.2%, and 27.2% were good, moderate, and poor blastocysts, respectively, based on the ranking model.
- These results indicate that the majority of euploid blastocysts were good and moderate and that the optimal sequence for transfer should be prioritized as good, followed by moderate and then poor blastocysts.



83 samples



213 euploid blastocysts



# Conclusions

- I. Transcriptomic analysis of blastocysts offers a novel approach for predicting embryo implantation potential, which can be utilized to optimize clinical embryo selection. The ranking system may be effective in reducing the times and costs involved in achieving a clinical pregnancy.
- II. Machine learning models, built with DEGs from embryos with known pregnancy outcomes, achieved AUCs of 0.87 (RF), 0.78 (SVM), and 0.74 (LDA) in independent validation, indicating their predictive power.
- III. The “Good prob” group, with an 88.6% implantation rate, demonstrates the potential of combined DNA and RNA analysis to enhance PGT clinical outcomes.
- IV. Further validation is needed through larger, multi-center prospective studies; currently, two single-center clinical trials are underway to assess the model's clinical efficacy.

# Acknowledgement


- All the patients who participated in this study.
- Groups from Sir Run Run Shaw Hospital and Yikon Genomics/Yikon Medical.



Dr. Jiamin Jin



Dr. Xiaomei Tong



Prof. Songying Zhang



Jieliang Ma



Dr. Yangyun Zou



Dr. Sijia Lu



For the Health

**Thank you for attention!**

of Billions